Elanco announces marketing authorization of Increxxa<sup>TM</sup> in Europe
Antimicrobial INCREXXA™ (tulathromycin injection) helps address the global challenge of respiratory disease.
Elanco Animal Health Incorporated (NYSE: ELAN) today announced the European Commission adopted the decision to grant marketing authorization of INCREXXA™ (tulathromycin injection) in the European Union. The marketing authorisation has been granted for Elanco’s product Increxxa 100mg/ml solution for injection for cattle, pigs, and sheep and Increxxa 25 mg/ml solution for injection for swine.
Increxxa injectable solution is a new veterinary medicine containing tulathromycin, a broad-spectrum antimicrobial (macrolide). Increxxa will be indicated for the treatment and metaphylaxis of bovine and swine respiratory disease, Bovine IBK (pinkeye), and in sheep for the treatment of early-stage infectious pododermatitis (footrot).
Adding Increxxa to Elanco’s bovine and swine respiratory disease portfolios reflects our commitment to delivering a portfolio of solutions that benefit the health and welfare of animals, and helps our customers address the global challenge of respiratory disease.